These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 21102422)

  • 1. A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer.
    Nakao A; Kasuya H; Sahin TT; Nomura N; Kanzaki A; Misawa M; Shirota T; Yamada S; Fujii T; Sugimoto H; Shikano T; Nomoto S; Takeda S; Kodera Y; Nishiyama Y
    Cancer Gene Ther; 2011 Mar; 18(3):167-75. PubMed ID: 21102422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I Dose-escalation Clinical Trial of HF10 Oncolytic Herpes Virus in 17 Japanese Patients with Advanced Cancer.
    Kasuya H; Kodera Y; Nakao A; Yamamura K; Gewen T; Zhiwen W; Hotta Y; Yamada S; Fujii T; Fukuda S; Tsurumaru N; Kuwahara T; Kikumori T; Koide Y; Fujimoto Y; Nakashima T; Hirooka Y; Shiku H; Tanaka M; Takesako K; Kondo T; Aleksic B; Kawashima H; Goto H; Nishiyama Y
    Hepatogastroenterology; 2014 May; 61(131):599-605. PubMed ID: 26176043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer.
    Hirooka Y; Kasuya H; Ishikawa T; Kawashima H; Ohno E; Villalobos IB; Naoe Y; Ichinose T; Koyama N; Tanaka M; Kodera Y; Goto H
    BMC Cancer; 2018 May; 18(1):596. PubMed ID: 29801474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination treatment of human pancreatic cancer xenograft models with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib and oncolytic herpes simplex virus HF10.
    Yamamura K; Kasuya H; Sahin TT; Tan G; Hotta Y; Tsurumaru N; Fukuda S; Kanda M; Kobayashi D; Tanaka C; Yamada S; Nakayama G; Fujii T; Sugimoto H; Koike M; Nomoto S; Fujiwara M; Tanaka M; Kodera Y
    Ann Surg Oncol; 2014 Feb; 21(2):691-8. PubMed ID: 24170435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experiment of mutant herpes simplex virus HF10 therapy for cancer.
    Nakao A; Takeda S; Shimoyama S; Kasuya H; Kimata H; Teshigahara O; Sawaki M; Kikumori T; Kodera Y; Nagasaka T; Goshima F; Nishiyama Y; Imai T
    Curr Cancer Drug Targets; 2007 Mar; 7(2):169-74. PubMed ID: 17346108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of novel oncolytic virus HF10 on cellular components of the tumor microenviroment in patients with recurrent breast cancer.
    Sahin TT; Kasuya H; Nomura N; Shikano T; Yamamura K; Gewen T; Kanzaki A; Fujii T; Sugae T; Imai T; Nomoto S; Takeda S; Sugimoto H; Kikumori T; Kodera Y; Nishiyama Y; Nakao A
    Cancer Gene Ther; 2012 Apr; 19(4):229-37. PubMed ID: 22193629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft.
    Tan G; Kasuya H; Sahin TT; Yamamura K; Wu Z; Koide Y; Hotta Y; Shikano T; Yamada S; Kanzaki A; Fujii T; Sugimoto H; Nomoto S; Nishikawa Y; Tanaka M; Tsurumaru N; Kuwahara T; Fukuda S; Ichinose T; Kikumori T; Takeda S; Nakao A; Kodera Y
    Int J Cancer; 2015 Apr; 136(7):1718-30. PubMed ID: 25156870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
    Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
    Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.
    Park BH; Hwang T; Liu TC; Sze DY; Kim JS; Kwon HC; Oh SY; Han SY; Yoon JH; Hong SH; Moon A; Speth K; Park C; Ahn YJ; Daneshmand M; Rhee BG; Pinedo HM; Bell JC; Kirn DH
    Lancet Oncol; 2008 Jun; 9(6):533-42. PubMed ID: 18495536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic activity of avian influenza virus in human pancreatic ductal adenocarcinoma cell lines.
    Kasloff SB; Pizzuto MS; Silic-Benussi M; Pavone S; Ciminale V; Capua I
    J Virol; 2014 Aug; 88(16):9321-34. PubMed ID: 24899201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in oncolytic adenovirus therapy for pancreatic cancer.
    Nattress CB; Halldén G
    Cancer Lett; 2018 Oct; 434():56-69. PubMed ID: 29981812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reshaping the Immune Microenvironment by Oncolytic Herpes Simplex Virus in Murine Pancreatic Ductal Adenocarcinoma.
    Zhang L; Wang W; Wang R; Zhang N; Shang H; Bi Y; Chen D; Zhang C; Li L; Yin J; Zhang H; Cao Y
    Mol Ther; 2021 Feb; 29(2):744-761. PubMed ID: 33130310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suitability of a US3-inactivated HSV mutant (L1BR1) as an oncolytic virus for pancreatic cancer therapy.
    Kasuya H; Nishiyama Y; Nomoto S; Goshima F; Takeda S; Watanabe I; Nomura N; Shikano T; Fujii T; Kanazumi N; Nakao A
    Cancer Gene Ther; 2007 Jun; 14(6):533-42. PubMed ID: 17415379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients.
    Li JL; Liu HL; Zhang XR; Xu JP; Hu WK; Liang M; Chen SY; Hu F; Chu DT
    Gene Ther; 2009 Mar; 16(3):376-82. PubMed ID: 19092859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivation of the DNA-sensing pathway facilitates oncolytic herpes simplex virus inhibition of pancreatic ductal adenocarcinoma growth.
    Zhang N; Guan Y; Li J; Yu J; Yi T
    Int Immunopharmacol; 2023 Nov; 124(Pt B):110969. PubMed ID: 37774484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer.
    Kimata H; Imai T; Kikumori T; Teshigahara O; Nagasaka T; Goshima F; Nishiyama Y; Nakao A
    Ann Surg Oncol; 2006 Aug; 13(8):1078-84. PubMed ID: 16865590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to intra-arterial oncolytic virotherapy with the herpes virus NV1020 evaluated by [18F]fluorodeoxyglucose positron emission tomography and computed tomography.
    Sze DY; Iagaru AH; Gambhir SS; De Haan HA; Reid TR
    Hum Gene Ther; 2012 Jan; 23(1):91-7. PubMed ID: 21895536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.
    Kaufman HL; Kim DW; DeRaffele G; Mitcham J; Coffin RS; Kim-Schulze S
    Ann Surg Oncol; 2010 Mar; 17(3):718-30. PubMed ID: 19915919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy.
    Menotti L; Avitabile E
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer.
    Tsuji T; Nakamori M; Iwahashi M; Nakamura M; Ojima T; Iida T; Katsuda M; Hayata K; Ino Y; Todo T; Yamaue H
    Int J Cancer; 2013 Jan; 132(2):485-94. PubMed ID: 22729516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.